89% of patients with Mast Cell Activation Syndrome (MCAS) had significant reduction in symptoms from GLP-1RAs. It is thought that these drugs stabilize mast cells and reduce inflammation. The authors recommend future randomized trials of these drugs in patients with #LongCOVID.
sciencedirect.com
Utility of Glucagon-Like-Peptide-1-Receptor Agonists in Mast Cell Activation Syndrome
Introduction: Mast cell (MC) activation syndrome (MCAS) is a collection of illnesses rooted in inappropriate MC activation with little to no neoplasti…